102 related articles for article (PubMed ID: 8621234)
1. Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger A; Egle A; Kos M; Hittmair A; Maly K; Greil R
Int J Cancer; 1996 Feb; 65(4):498-505. PubMed ID: 8621234
[TBL] [Abstract][Full Text] [Related]
2. Growth regulatory pathways in myeloma. Evidence for autocrine oncostatin M expression.
Westendorf JJ; Jelinek DF
J Immunol; 1996 Oct; 157(7):3081-8. PubMed ID: 8816418
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of flow cytometric detection of cell surface interleukin-6 receptors in human myeloma cell lines.
Chen YH; Feng XX; Hagen K
Clin Lab Haematol; 1996 Sep; 18(3):161-9. PubMed ID: 8939386
[TBL] [Abstract][Full Text] [Related]
4. Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
Diamant M; Hansen MB; Rieneck K; Svenson M; Yasukawa K; Bendtzen K
Leuk Res; 1996 Apr; 20(4):291-301. PubMed ID: 8642840
[TBL] [Abstract][Full Text] [Related]
5. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis.
Levy Y; Labaume S; Colombel M; Brouet JC
Clin Exp Immunol; 1996 Apr; 104(1):167-72. PubMed ID: 8603522
[TBL] [Abstract][Full Text] [Related]
7. A monoclonal anti-human IL-6 receptor antibody inhibits the proliferation of human myeloma cells.
Huang YW; Vitetta ES
Hybridoma; 1993 Oct; 12(5):621-30. PubMed ID: 8300137
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M
Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407
[TBL] [Abstract][Full Text] [Related]
9. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells.
Wang YD; De Vos J; Jourdan M; Couderc G; Lu ZY; Rossi JF; Klein B
Oncogene; 2002 Apr; 21(16):2584-92. PubMed ID: 11971193
[TBL] [Abstract][Full Text] [Related]
10. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells.
Kang HS; Lee BS; Yang Y; Park CW; Ha HJ; Pyun KH; Choi I
Cell Immunol; 1996 Mar; 168(2):174-83. PubMed ID: 8640863
[TBL] [Abstract][Full Text] [Related]
11. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop.
Jernberg-Wiklund H; Pettersson M; Carlsson M; Nilsson K
Leukemia; 1992 Apr; 6(4):310-8. PubMed ID: 1588793
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of interleukin-6 receptors by interleukin-6 and interferons in multiple myeloma cell lines.
Lasfar A; Wietzerbin J; Billard C
Eur J Immunol; 1994 Jan; 24(1):124-30. PubMed ID: 8020547
[TBL] [Abstract][Full Text] [Related]
14. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 6 receptor superantagonists are potent inducers of human multiple myeloma cell death.
Demartis A; Bernassola F; Savino R; Melino G; Ciliberto G
Cancer Res; 1996 Sep; 56(18):4213-8. PubMed ID: 8797594
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line.
Ozaki S; Wolfenbarger D; deBram-Hart M; Kanangat S; Weiss DT; Solomon A
Leukemia; 1994 Dec; 8(12):2207-13. PubMed ID: 7528862
[TBL] [Abstract][Full Text] [Related]
17. Epitope peptides from interleukin-6 receptor which inhibit the growth of human myeloma cells.
Halimi H; Eisenstein M; Oh JW; Revel M; Chebath J
Eur Cytokine Netw; 1995; 6(3):135-43. PubMed ID: 8589270
[TBL] [Abstract][Full Text] [Related]
18. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
19. Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.
Schwabe M; Brini AT; Bosco MC; Rubboli F; Egawa M; Zhao J; Princler GL; Kung HF
J Clin Invest; 1994 Dec; 94(6):2317-25. PubMed ID: 7989587
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]